H. nipponia / H. tianjinensis Monomeric Decorsins
Monomeric and oligomeric decorsins + hirudins + hirudin-like factors across H. nipponia and H. tianjinensis — Kalatehjari 2026 recombinant platelet-aggregation characterization.
Mechanistic Evidence Box
Preclinical / mechanistic: Evidence is preclinical (in vitro, animal models, or mechanism-of-action research). Clinical efficacy in humans has not been established.- Page type
- Compound profile
- Evidence type
- Preclinical / biochemical characterization
- Evidence level
- In vitro
- Drug vs leech
- Recombinant (genetically expressed)
- Safety domains
- Bleeding
Clinical translation limit
H. nipponia / H. tianjinensis monomeric decorsin antiplatelet activity in vitro does NOT establish clinical efficacy. No FDA-approved derivative; neither species is on the FDA K040187 cleared device species list.
Molecular Profile
- Category
- Antiplatelet
- Evidence tier
- Preclinical
- Source species
- Hirudo nipponia + Hirudo tianjinensis
- Discovered
- 2026 · Kalatehjari P et al.
Biological Targets
- → platelet GPIIb/IIIa receptor; thrombin (paralogous hirudins)
Key Citations
- Kalatehjari P et al. (2026), Parasitol Res · PMID 41653280
External Resources
Related Antiplatelet Compounds
Calin
Anti-platelet adhesion protein that blocks von Willebrand factor–collagen binding.
Saratin
Anti-platelet adhesion protein blocking collagen-mediated platelet activation.
Decorsin
RGD-containing peptide that inhibits the platelet GP IIb/IIIa receptor; the drug eptifibatide was modelled on snake-venom barbourin, not on decorsin.
Ornatin
RGD-peptide GP IIb/IIIa antagonist — sister molecule to decorsin from a different leech species.